Literature DB >> 17992500

[Update on chemoinfusion and chemoembolization treatments].

A Lubienski1, M Simon, K Lubienski, J Gellissen, R-T Hoffmann, T F Jakobs, T Helmberger.   

Abstract

In the last two decades image-guided interventional catheterizations and percutaneous ablative regional treatment procedures have revolutionized the therapy of nonresectable primary and secondary liver tumours. A distinction is made between chemoablative procedures and thermo- and radioablative procedures. The main chemoablative interventions are transarterial infusion chemotherapy (HAIC; hepatic arterial infusion chemotherapy) and transarterial (chemo-)embolization (TACE/TAE). The object of the transarterial treatment procedures is to deliver the highest possible concentration of a chemotherapy agent or combination of chemotherapy agents directly into the tumour by way of the blood vessels supplying it, while at the same time keeping the systemic effects of the drugs as small as possible. Transarterial chemoperfusion to the liver can be applied in the treatment of all primary and secondary hepatic tumours, but the main indications are hepatocellular carcinoma (HCC) and metastases from colorectal primary tumours.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17992500     DOI: 10.1007/s00117-007-1587-4

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.803


  70 in total

1.  New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer.

Authors:  Kelvin Hong; Afsheen Khwaja; Eleni Liapi; Michael S Torbenson; Cristos S Georgiades; Jean-Francois H Geschwind
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy.

Authors:  Takuji Yamagami; Takeharu Kato; Osamu Tanaka; Tatsuya Hirota; Tsunehiko Nishimura
Journal:  J Vasc Interv Radiol       Date:  2005-04       Impact factor: 3.464

3.  Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.

Authors:  Chien-Chang Lee; Yuan-Huei Wu; Shen-Hung Chung; Wen-Jone Chen
Journal:  Oncologist       Date:  2006-01

4.  [Investigation of bile duct injury after transcatheter arterial chemoembolization].

Authors:  Mao-qiang Wang; Ru-hong Shao; Hui-yi Ye; Zhi-qiang Wang; Zhong-pu Wang; Feng-yong Liu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2005-10

5.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  L Lladó; J Virgili; J Figueras; C Valls; J Dominguez; A Rafecas; J Torras; J Fabregat; J Guardiola; E Jaurrieta
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

6.  A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma.

Authors:  Annie O Chan; Man-Fung Yuen; Chee-Kin Hui; Wai-Kuen Tso; Ching-Lung Lai
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

7.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

Authors:  María Varela; María Isabel Real; Marta Burrel; Alejandro Forner; Margarita Sala; Mercé Brunet; Carmen Ayuso; Lluis Castells; Xavier Montañá; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2006-11-29       Impact factor: 25.083

8.  Hepatic arterial port systems for treatment of liver metastases: factors affecting patency and adverse events.

Authors:  Jens Ricke; Bert Hildebrandt; Alexandra Miersch; Annett Nicolaou; Guesjal Warschewske; Ulf Teichgräber; Enrique Lopez Hänninen; Hanno Riess; Roland Felix
Journal:  J Vasc Interv Radiol       Date:  2004-08       Impact factor: 3.464

Review 9.  Management of hepatic metastases.

Authors:  M A Choti; G B Bulkley
Journal:  Liver Transpl Surg       Date:  1999-01

10.  DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.

Authors:  Andrew L Lewis; M Victoria Gonzalez; Andrew W Lloyd; Brenda Hall; Yiqing Tang; Sean L Willis; Simon W Leppard; Laura C Wolfenden; Rosemary R Palmer; Peter W Stratford
Journal:  J Vasc Interv Radiol       Date:  2006-02       Impact factor: 3.464

View more
  6 in total

1.  Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.

Authors:  Yonghua Bi; Dechao Jiao; Yang Wang; Xinwei Han; Jianzhuang Ren
Journal:  World J Surg Oncol       Date:  2022-07-12       Impact factor: 3.253

2.  [Metastases of colorectal carcinoma].

Authors:  S Clasen; H Rempp; P L Pereira
Journal:  Radiologe       Date:  2008-11       Impact factor: 0.635

Review 3.  [Arterial embolization of hepatic metastases from neuroendocrine tumors].

Authors:  M Libicher; H Bovenschulte
Journal:  Radiologe       Date:  2009-03       Impact factor: 0.635

4.  Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC).

Authors:  Xiao-Jun Lin; Qi-Jiong Li; Xiang-Ming Lao; Han Yang; Sheng-Ping Li
Journal:  BMC Cancer       Date:  2015-10-15       Impact factor: 4.430

5.  Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients.

Authors:  Tatjana Gruber-Rouh; Marcel Langenbach; Nagy N N Naguib; Nour-Eldin M Nour-Eldin; Thomas J Vogl; Stephan Zangos; Martin Beeres
Journal:  World J Clin Oncol       Date:  2017-08-10

6.  Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis.

Authors:  Chaobin He; Yu Zhang; Xiaojun Lin
Journal:  J Gastrointest Surg       Date:  2018-02-12       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.